Validation of MicroRNA Biomarkers for Alzheimer's Disease in Human Cerebrospinal Fluid

Jack T. Wiedrick, Jay I. Phillips, Theresa A. Lusardi, Trevor J. McFarland, Babett Lind, Ursula S. Sandau, Christina (Chris) Harrington, Jodi Lapidus, Douglas R. Galasko, Joseph Quinn, Julie Saugstad

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We previously discovered microRNAs (miRNAs) in cerebrospinal fluid (CSF) that differentiate Alzheimer's disease (AD) patients from Controls. Here we examined the performance of 37 candidate AD miRNA biomarkers in a new and independent cohort of CSF from 47 AD patients and 71 Controls on custom TaqMan arrays. We employed a consensus ranking approach to provide an overall priority score for each miRNA, then used multimarker models to assess the relative contributions of the top-ranking miRNAs to differentiate AD from Controls. We assessed classification performance of the top-ranking miRNAs when combined with apolipoprotein E4 (APOE4) genotype status or CSF amyloid-β 42 (Aβ 42):total tau (T-tau) measures. We also assessed whether miRNAs that ranked higher as AD markers correlate with Mini-Mental State Examination (MMSE) scores. We show that of 37 miRNAs brought forth from the discovery study, 26 miRNAs remained viable as candidate biomarkers for AD in the validation study. We found that combinations of 6-7 miRNAs work better to identify AD than subsets of fewer miRNAs. Of 26 miRNAs that contribute most to the multimarker models, 14 have higher potential than the others to predict AD. Addition of these 14 miRNAs to APOE4 status or CSF Aβ 42:T-tau measures significantly improved classification performance for AD. We further show that individual miRNAs that ranked higher as AD markers correlate more strongly with changes in MMSE scores. Our studies validate that a set of CSF miRNAs serve as biomarkers for AD, and support their advancement toward development as biomarkers in the clinical setting.

Original languageEnglish (US)
Pages (from-to)875-891
Number of pages17
JournalJournal of Alzheimer's Disease
Volume67
Issue number3
DOIs
StatePublished - Jan 1 2019

Fingerprint

MicroRNAs
Cerebrospinal Fluid
Alzheimer Disease
Biomarkers
Apolipoprotein E4
Validation Studies
Amyloid
Consensus
Genotype

Keywords

  • Alzheimer's disease
  • amyloid-β 42
  • apolipoprotein E
  • biomarkers
  • cerebrospinal fluid
  • microRNA
  • Mini-Mental State Examination
  • total tau

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Wiedrick, J. T., Phillips, J. I., Lusardi, T. A., McFarland, T. J., Lind, B., Sandau, U. S., ... Saugstad, J. (2019). Validation of MicroRNA Biomarkers for Alzheimer's Disease in Human Cerebrospinal Fluid. Journal of Alzheimer's Disease, 67(3), 875-891. https://doi.org/10.3233/JAD-180539

Validation of MicroRNA Biomarkers for Alzheimer's Disease in Human Cerebrospinal Fluid. / Wiedrick, Jack T.; Phillips, Jay I.; Lusardi, Theresa A.; McFarland, Trevor J.; Lind, Babett; Sandau, Ursula S.; Harrington, Christina (Chris); Lapidus, Jodi; Galasko, Douglas R.; Quinn, Joseph; Saugstad, Julie.

In: Journal of Alzheimer's Disease, Vol. 67, No. 3, 01.01.2019, p. 875-891.

Research output: Contribution to journalArticle

Wiedrick JT, Phillips JI, Lusardi TA, McFarland TJ, Lind B, Sandau US et al. Validation of MicroRNA Biomarkers for Alzheimer's Disease in Human Cerebrospinal Fluid. Journal of Alzheimer's Disease. 2019 Jan 1;67(3):875-891. https://doi.org/10.3233/JAD-180539
Wiedrick, Jack T. ; Phillips, Jay I. ; Lusardi, Theresa A. ; McFarland, Trevor J. ; Lind, Babett ; Sandau, Ursula S. ; Harrington, Christina (Chris) ; Lapidus, Jodi ; Galasko, Douglas R. ; Quinn, Joseph ; Saugstad, Julie. / Validation of MicroRNA Biomarkers for Alzheimer's Disease in Human Cerebrospinal Fluid. In: Journal of Alzheimer's Disease. 2019 ; Vol. 67, No. 3. pp. 875-891.
@article{01965fc0234b4b3aba54456e61f97dfa,
title = "Validation of MicroRNA Biomarkers for Alzheimer's Disease in Human Cerebrospinal Fluid",
abstract = "We previously discovered microRNAs (miRNAs) in cerebrospinal fluid (CSF) that differentiate Alzheimer's disease (AD) patients from Controls. Here we examined the performance of 37 candidate AD miRNA biomarkers in a new and independent cohort of CSF from 47 AD patients and 71 Controls on custom TaqMan arrays. We employed a consensus ranking approach to provide an overall priority score for each miRNA, then used multimarker models to assess the relative contributions of the top-ranking miRNAs to differentiate AD from Controls. We assessed classification performance of the top-ranking miRNAs when combined with apolipoprotein E4 (APOE4) genotype status or CSF amyloid-β 42 (Aβ 42):total tau (T-tau) measures. We also assessed whether miRNAs that ranked higher as AD markers correlate with Mini-Mental State Examination (MMSE) scores. We show that of 37 miRNAs brought forth from the discovery study, 26 miRNAs remained viable as candidate biomarkers for AD in the validation study. We found that combinations of 6-7 miRNAs work better to identify AD than subsets of fewer miRNAs. Of 26 miRNAs that contribute most to the multimarker models, 14 have higher potential than the others to predict AD. Addition of these 14 miRNAs to APOE4 status or CSF Aβ 42:T-tau measures significantly improved classification performance for AD. We further show that individual miRNAs that ranked higher as AD markers correlate more strongly with changes in MMSE scores. Our studies validate that a set of CSF miRNAs serve as biomarkers for AD, and support their advancement toward development as biomarkers in the clinical setting.",
keywords = "Alzheimer's disease, amyloid-β 42, apolipoprotein E, biomarkers, cerebrospinal fluid, microRNA, Mini-Mental State Examination, total tau",
author = "Wiedrick, {Jack T.} and Phillips, {Jay I.} and Lusardi, {Theresa A.} and McFarland, {Trevor J.} and Babett Lind and Sandau, {Ursula S.} and Harrington, {Christina (Chris)} and Jodi Lapidus and Galasko, {Douglas R.} and Joseph Quinn and Julie Saugstad",
year = "2019",
month = "1",
day = "1",
doi = "10.3233/JAD-180539",
language = "English (US)",
volume = "67",
pages = "875--891",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "3",

}

TY - JOUR

T1 - Validation of MicroRNA Biomarkers for Alzheimer's Disease in Human Cerebrospinal Fluid

AU - Wiedrick, Jack T.

AU - Phillips, Jay I.

AU - Lusardi, Theresa A.

AU - McFarland, Trevor J.

AU - Lind, Babett

AU - Sandau, Ursula S.

AU - Harrington, Christina (Chris)

AU - Lapidus, Jodi

AU - Galasko, Douglas R.

AU - Quinn, Joseph

AU - Saugstad, Julie

PY - 2019/1/1

Y1 - 2019/1/1

N2 - We previously discovered microRNAs (miRNAs) in cerebrospinal fluid (CSF) that differentiate Alzheimer's disease (AD) patients from Controls. Here we examined the performance of 37 candidate AD miRNA biomarkers in a new and independent cohort of CSF from 47 AD patients and 71 Controls on custom TaqMan arrays. We employed a consensus ranking approach to provide an overall priority score for each miRNA, then used multimarker models to assess the relative contributions of the top-ranking miRNAs to differentiate AD from Controls. We assessed classification performance of the top-ranking miRNAs when combined with apolipoprotein E4 (APOE4) genotype status or CSF amyloid-β 42 (Aβ 42):total tau (T-tau) measures. We also assessed whether miRNAs that ranked higher as AD markers correlate with Mini-Mental State Examination (MMSE) scores. We show that of 37 miRNAs brought forth from the discovery study, 26 miRNAs remained viable as candidate biomarkers for AD in the validation study. We found that combinations of 6-7 miRNAs work better to identify AD than subsets of fewer miRNAs. Of 26 miRNAs that contribute most to the multimarker models, 14 have higher potential than the others to predict AD. Addition of these 14 miRNAs to APOE4 status or CSF Aβ 42:T-tau measures significantly improved classification performance for AD. We further show that individual miRNAs that ranked higher as AD markers correlate more strongly with changes in MMSE scores. Our studies validate that a set of CSF miRNAs serve as biomarkers for AD, and support their advancement toward development as biomarkers in the clinical setting.

AB - We previously discovered microRNAs (miRNAs) in cerebrospinal fluid (CSF) that differentiate Alzheimer's disease (AD) patients from Controls. Here we examined the performance of 37 candidate AD miRNA biomarkers in a new and independent cohort of CSF from 47 AD patients and 71 Controls on custom TaqMan arrays. We employed a consensus ranking approach to provide an overall priority score for each miRNA, then used multimarker models to assess the relative contributions of the top-ranking miRNAs to differentiate AD from Controls. We assessed classification performance of the top-ranking miRNAs when combined with apolipoprotein E4 (APOE4) genotype status or CSF amyloid-β 42 (Aβ 42):total tau (T-tau) measures. We also assessed whether miRNAs that ranked higher as AD markers correlate with Mini-Mental State Examination (MMSE) scores. We show that of 37 miRNAs brought forth from the discovery study, 26 miRNAs remained viable as candidate biomarkers for AD in the validation study. We found that combinations of 6-7 miRNAs work better to identify AD than subsets of fewer miRNAs. Of 26 miRNAs that contribute most to the multimarker models, 14 have higher potential than the others to predict AD. Addition of these 14 miRNAs to APOE4 status or CSF Aβ 42:T-tau measures significantly improved classification performance for AD. We further show that individual miRNAs that ranked higher as AD markers correlate more strongly with changes in MMSE scores. Our studies validate that a set of CSF miRNAs serve as biomarkers for AD, and support their advancement toward development as biomarkers in the clinical setting.

KW - Alzheimer's disease

KW - amyloid-β 42

KW - apolipoprotein E

KW - biomarkers

KW - cerebrospinal fluid

KW - microRNA

KW - Mini-Mental State Examination

KW - total tau

UR - http://www.scopus.com/inward/record.url?scp=85061726190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061726190&partnerID=8YFLogxK

U2 - 10.3233/JAD-180539

DO - 10.3233/JAD-180539

M3 - Article

VL - 67

SP - 875

EP - 891

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 3

ER -